ArticlePloS one2012

Dacarbazine and the agonistic TRAIL receptor-2 antibody lexatumumab induce synergistic anticancer effects in melanoma.

Birgit Engesæter et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.